Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: A single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers

Clinical Therapeutics

Volumn 31, Issue 11, 2009, Pages 2755-2764

  Kim, Bo Hyung ^a   Shin, Kwang Hee ^a   Kim, JaeWoo ^a   Lim, Kyoung Soo ^a   Kim, Kyu pyo ^a   Kim, Jung Ryul ^a   Cho, Joo Youn ^a   Shin, Sang Goo ^a   Jang, In Jin ^a   Yu, Kyung Sang ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Amaryl M 1 500 mg; Amaryl M 2 500 mg; fixed dose combination; glimepiride; metformin; pharmacokinetics

Indexed keywords

AMARYL M; ANTIBIOTIC AGENT; GLIMEPIRIDE; METFORMIN; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BIRTH DEFECT; CLINICAL TRIAL; COLD SWEAT; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EPIGASTRIC DISCOMFORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITALIZATION; HUMAN; HUMAN EXPERIMENT; KOREA; LABORATORY TEST; LACERATION; LETHARGY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN TINGLING; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; VOLUNTEER; WEAKNESS;

ADULT; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DRUG COMBINATIONS; FASTING; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; SULFONYLUREA COMPOUNDS; TABLETS; YOUNG ADULT;

EID: 74549168076     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.001     Document Type: Article

References (14)

1. Centers for Disease Control and Prevention (CDC), and Department of Health and Human Services. Crude and ageadjusted incidence of diagnosed diabetes per 1,000 population aged 18-79 years, United States (1980-2007). http://www.cdc.gov/diabetes/statistics/incidence/fig2.htm Accessed July 28, 2009
2. Powers A.C. Diabetes mellitus. In: Fauci A.S., Kasper D.L., Longo D.L., et al. (Eds). Harrison's Principles of Internal Medicine. 17th ed. (2008), McGraw-Hill Medical, New York, NY 2275-2304
3. Charpentier G., Fleury F., Kabir M., et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med. 18 (2001) 828-834
4. Lee S.H., Lee I.K., Baik S.H., et al. Comparison of the efficacy and safety of glimepiride/metformin fixed combination versus free combination in patients with type 2 diabetes: Multicenter, randomized, controlled trial. J Korean Diabetes Assoc. 30 (2006) 466-475
5. Jung T.R., Hwang S.W., Lee J.U., et al. Comparative consistency between obesity determination standards using body mass index and ideal body weight. J Korean Acad Fam Med. 22 (2001) 1765-1771
6. International Conference on Harmonisation Expert Working Group. ICH harmonised tripartite guideline: Guideline for good clinical practice E6(R1). http://www.ich.org/LOB/media/MEDIA482.pdf Accessed July 28, 2009
7. Kim H., Chang K.Y., Lee H.J., and Han S.B. Determination of glimepiride in human plasma by liquid chromatographyelectrospray ionization tandem mass spectrometry. Bull Korean Chem Soc. 25 (2004) 109-114
8. Nyberg J.S. Paper PO05: The paired T-Test Does PROC MIXED produce the same results as PROC TTEST?. Pharmaceutical Industry SAS Users Group Annual Meeting (2004). http://www.lexjansen.com/pharmasug/2004/posters/po05.pdf Accessed October 15, 2009
9. Bristol-Myers Squibb Company. Glucophage (metformin hydrochloride tablets) [prescribing information]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdf Accessed October 15, 2009
10. sanofi-aventis U.S., LLC. Amaryl (glimepiride tablets) prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020496s021lbl.pdf Accessed October 15, 2009
11. Vanderpoel D.R., Hussein M.A., Watson-Heidari T., and Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: A retrospective database analysis. Clin Ther. 26 (2004) 2066-2075
12. Shukla U.A., Chi E.M., and Lehr K.H. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Ann Pharmacother. 38 (2004) 30-35
13. Donnelly L.A., Doney A.S., Hattersley A.T., et al. The effect of obesity on glycaemic response to metformin or sulphonylureas in type 2 diabetes. Diabet Med. 23 (2006) 128-133
14. Sambol N.C., Brookes L.G., Chiang J., et al. Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol. 42 (1996) 510-512